Achilles adds £100M to move neoantigen T cell therapy into the clinic

Achilles added blue chip investors in its series B round to finance the progression of its neoantigen T cell therapy platform into the clinic.

New investor RA Capital led the £100 million ($121.3 million) series B round for Achilles Therapeutics

Read the full 396 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE